Oncology/Hematology
Lymphoma
More in Lymphoma
Systematic review and meta-analysis finds CAR T-cell-specific toxicities only account for 11.5%
Responses to pirtobrutinib observed in patients with previously treated disease
Better survival in one registry study, detriment with class I HLA mismatch in another
News, features, and commentary about cancer-related issues
News, features, and commentary about cancer-related issues
New iteration of denileukin diftitox led to objective responses in 36% of pretreated patients
News, features, and commentary about cancer-related issues
77% of pregnancies resulted in live births
News, features, and commentary about cancer-related issues
Durable response possible with treatment targeting a different antigen
R-CHOP plus venetoclax falls short, while R-CHOP with HDAC inhibitor shows promise
Incidence significantly reduced with two types of exercises versus usual care
News, features, and commentary about cancer-related issues
Our panel of experts discusses mosunetuzumab/polatuzumab vedotin for relapsed/refractory patients
